US Patent

US7504509 — Compounds and methods for development of Ret modulators

Composition of Matter · Assigned to Plexxikon Inc · Expires 2026-10-22 · 0y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds that modulate the Ret protein and methods for developing such compounds, including crystal structures of Ret surrogates.

USPTO Abstract

Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.

Drugs covered by this patent

Patent Metadata

Patent number
US7504509
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-10-22
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Plexxikon Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.